RINVOQ  is indicated for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to MTX. RINVOQ may be used as monotherapy or in combination with MTX or other nonbiologic DMARDs. 
 

RINVOQ  is indicated for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to MTX. RINVOQ may be used as monotherapy or in combination with MTX or other nonbiologic DMARDs. 
 

Consult the Product Monograph at rinvoq.ca/pm for information about contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-888-704-8271.